Abstract 15P
Background
Although electrocautery is popularly used for the skin flap preparations at the time of mastectomy, we have been making the skin flap using the tumescent technique for the protects of the wound and skin flap since 2012 in our department. The aim of the study is to examine the differences of the clinical outcomes by between the surgeons (specialist who is familiar with breast surgery vs non-special surgeons).
Methods
166 patients who underwent the reconstruction after 1ststage of mastectomy with the tumescent technique at our hospital from March 2012 to December 2018 were enrolled. Tumescent technique; just before skin incision, we injected the tumescent solusions (200ml of physiological saline, 1mg of adrenaline, 20ml of xylocaine) subcutaneously into the breast and we started the sharp skin incision containing the tumor and around the areola like the spindle shape. If the tumor is close to the skin, we resected the skin just above tumor. We separated between subcutaneous and mammary tissue, and made the skin flap widely using the mechenbaum scissor and the wound retractor for protect the skin cutting edge. The most important things of this technique are to get the viewing field using the wound retractor with light and and the hemostasis exactly using McCannd forceps.
Results
patients characteristics is mean age 47.9 years (25-73 years), BMI is mean 21.1 (16.4-35.4), complication disease are 4 cases of hypertension, 4 cases of diabetes mellitus, 3 cases of radiotherapy previously, we performed surgery for 52 cases of DICS, for 114 cases of the invasive cancer including 10 cases of the axillary lymph node dissections, specialist performed 100 cases of mastectomy, on the other hand non-special surgeons performed 66 cases of mastectomy. Mean operation time is 56 min and 62 min (p = 0.314), there are no significant differences between the weight of the resected tissue and operation time (p = 0.062. Mean blood loss is 54ml each. 49 case (29%) of the mild necrosis of the skin, and 8 cases (4.7%) of hematoma were totally occurred after surgery, There are also no significant differences between specialist and non-special surgeons.
Conclusions
Mastectomy using the tumescent technique is easy and safe for not only specialist but also non-special surgeons.
Clinical trial identification
Editorial acknowledgement
Tissue expander and Inplants were approved for clinical use in Japan in July 2013.Since 2013, the reconstruction after mastectomy has been increasing year by year in Japan.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract